Search Results
Your search for Matthew matches 8054 pages
Showing 7451 - 7500Poorer Psychosexual Functioning in Adult Female Survivors of Childhood Cancer
In an analysis in the Childhood Cancer Survivor Study population reported in the Journal of Clinical Oncology, Ford et al found that adult woman survivors of childhood cancer have poorer psychosexual function than their siblings without childhood cancer. Risk factors for poorer function included...
Updated Recommendations for Evaluation, Staging, and Response Assessment for Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification
Updated recommendations (the Lugano Classification) for initial evaluation, staging, and assessment of response in patients with Hodgkin lymphoma and non-Hodgkin lymphoma (NHL) have been presented in the Journal of Clinical Oncology by Cheson et al. The recommendations are the result of two...
ICML Imaging Working Group Issues Updated Guidelines on PET-CT for Staging and Response Assessment for FDG-Avid Lymphomas
Barrington et al in the International Conference on Malignant Lymphomas Imaging Working Group have presented updated consensus guidelines on 18F-fluorodeoxyglucose (FDG) positron-emission tomography (PET)-computed tomography (CT) for staging and response assessment for FDG-avid lymphomas. The...
Analysis of Randomized Bisphosphonate Osteoporosis Trials Indicates No Reduction in Risk of Postmenopausal Breast Cancer
Observational studies have suggested a potential effect of bisphosphonate treatment for osteoporosis in reducing risk of breast cancer in postmenopausal women. However, an analysis of the randomized FIT trial of alendronate and HORIZON-PFT trial of zoledronic acid reported in JAMA Internal Medicine ...
Body Mass Index Positively Associated With Many Cancers in UK Study
In a UK population-based cohort study of associations between body mass index (BMI) and 22 specific cancers reported in The Lancet by Bhaskaran et al, positive associations were found for most cancers and were strongest for uterine, gallbladder, kidney, cervix, thyroid, liver, colon, ovarian, and...
Proposed Modification Incorporating Depth of Invasion in Primary Staging for Oral Cancer
In an analysis reported in JAMA Otolaryngology-Head & Neck Surgery, the International Consortium for Outcome Research (ICOR) in Head and Neck Cancer proposed modifying the current American Joint Committee on Cancer (AJCC) staging system for oral cancer to include depth of invasion. A model...
NeoALTTO Trial Shows No Benefit of Lapatinib Plus Trastuzumab in Secondary Survival Endpoints in HER2-Positive Early Breast Cancer
The phase III NeoALTTO trial showed a significantly improved pathologic complete response rate with lapatinib (Tykerb) plus trastuzumab (Herceptin) vs either alone in women with HER2-positive early breast cancer. As reported in The Lancet Oncology by de Azambuja et al, the combination was not...
ALK-Positivity Prevalence on Immunohistochemistry and FISH in Resected Stage I to III Lung Adenocarcinoma
The European Thoracic Oncology Platform Lungscape ALK project is investigating the prevalence and prognostic impact of ALK-positivity in resected lung adenocarcinoma in a primarily European population. As reported in the Journal of Clinical Oncology by Blackhall and colleagues, the project has...
Study Detects New ALK Mutations at Neuroblastoma Relapse
In a study reported in the Journal of Clinical Oncology, Schleiermacher et al found ALK mutations at relapse of neuroblastoma that were not present at diagnosis. They also found that subclonal mutations may be present at diagnosis with clonal expansion observed at relapse. The study involved...
NORCCAP Trial Shows Reduced Colorectal Cancer Incidence and Mortality With Flexible Sigmoidoscopy Screening at 11-Year Follow-up
The Norwegian Colorectal Cancer Prevention Trial comparing colorectal cancer screening with flexible sigmoidoscopy vs no screening showed no reduction in colorectal cancer incidence or mortality after 7 years of follow-up. As reported by Holme et al in JAMA, the 11-year follow-up shows significant...
ERSPC 13-Year Follow-up: Reduction in Prostate Cancer Mortality With PSA Screening, but High Overdiagnosis Rates Remain a Concern, Say Authors
The 13-year follow-up of the European Randomized Study of Screening for Prostate Cancer (ERSPC), reported by Schröder et al in The Lancet, showed that prostate-specific antigen (PSA) screening in men aged 55 to 69 years is associated with a 21% reduction in risk of prostate cancer mortality...
Similar 30-Day Outcomes With Laparoscopic vs Open Partial Hepatectomy in Single-Center Experience
In a single-center retrospective matched case-control study reported in JAMA Surgery, Franken et al found no significant differences in 30-day morbidity or mortality, positive margin status, major complications, hospital stay, or readmission rates for laparoscopic vs open partial hepatic resection...
Multiple Endocrine Neoplasia Type 1 Increases Risk of Breast Cancer
In a study reported in a letter to The New England Journal of Medicine, Dreijerink et al in the International Breast Cancer in MEN1 Study Group identified a high risk of breast cancer in women with multiple endocrine neoplasia type 1 (MEN1). MEN1 is caused by germline mutations in the MEN1...
Comprehensive Molecular Profiling of Lung Adenocarcinoma
The Cancer Genome Atlas Research Network has recently reported its comprehensive molecular profiling of lung adenocarcinoma in Nature. Findings included a high rate of somatic mutations including alterations in tumor-suppressor genes, chromatin-modifying genes, and RNA-splicing genes and suggested...
No Difference in Response Rate but Overall Survival Benefit With First-Line FOLFIRI/Cetuximab vs FOLFIRI/Bevacizumab in Metastatic Colorectal Cancer
In a European phase III FIRE-3 trial reported in The Lancet Oncology, Heinemann et al found no difference in response rate, the primary endpoint, between FOLFIRI (fluorouracil, leucovorin, and irinotecan) plus the anti-EGFR antibody cetuximab (Erbitux) vs FOLFIRI plus the anti-VEGF-A antibody...
Successful Vemurafenib Treatment of Progressive BRAF V600E–Mutated Anaplastic Pleomorphic Xanthoastrocytoma
The BRAF inhibitor vemurafenib (Zelboraf) is approved for treatment of BRAF-mutated metastatic melanoma. There are reports indicating that vemurafenib may be active in the treatment of intracranial neoplasms with BRAF mutations. As reported in the Journal of Clinical Oncology, Lee et al from...
Improvements in Overall Survival in Trilateral Retinoblastoma Due to Improved Chemotherapy and Earlier Detection
In a systematic review and meta-analysis reported in The Lancet Oncology, de Jong et al found a dramatic improvement in overall survival among children with trilateral retinoblastoma since 1995, reflecting increased use of conventional and high-dose chemotherapy with stem cell rescue in pineal and...
Negative PET/CT After One Cycle of Chemotherapy Strongly Predicts Favorable Outcome in Hodgkin Lymphoma
Negative 18F–fluorodeoxyglucose positron-emission tomography (PET)/computed tomography (CT) after two cycles of chemotherapy (PET2) has been shown to be associated with favorable prognosis in Hodgkin lymphoma. In a prospective study reported in the Journal of Clinical Oncology, Hutchings et...
Enzalutamide Increases Time to First Skeletal-Related Event and Improves Quality-of-Life Outcomes in Castration-Resistant Prostate Cancer
In the phase III international AFFIRM trial, enzalutamide (Xtandi) was shown to improve overall survival vs placebo in men with metastatic castration-resistant prostate cancer after progression on docetaxel. In an analysis of secondary endpoints reported in The Lancet Oncology, Fizazi et al found...
TP53, TET2, and DNMT3A Mutations Predict Poorer Survival After Hematopoietic Stem Cell Transplant in Patients With Myelodysplastic Syndrome
It is unclear whether somatic mutations that are strongly associated with phenotype and prognosis in myelodysplastic syndrome are also predictive of outcome after allogeneic hematopoietic stem cell transplantation. In a study reported in the Journal of Clinical Oncology, Bejar et al found that...
Phase II Study Supports Further Investigation of Neoadjuvant Carboplatin in Stage II to III Triple-Negative Breast Cancer
In the phase II Cancer and Leukemia Group B (CALGB) 40603/Alliance trial reported in the Journal of Clinical Oncology, Sikov et al found that the addition of carboplatin or bevacizumab (Avastin) to standard neoadjuvant chemotherapy significantly improved pathologic complete response rate in...
Study Quantifies Risk of Hereditary Breast Cancer in Carriers of PALB2 Mutations
In a study reported in The New England Journal of Medicine, Antoniou et al identified lifetime risk of breast cancer in families with germline loss-of-function mutations in PALB2. Estimated cumulative risk among female mutation carriers was 14% by 50 years of age and 35% by 70 years of age....
Adding Gemtuzumab Ozogamicin to Chemotherapy Improves Event-Free Survival but Not Overall Survival in Children and Adolescents With De Novo AML
In a Children’s Oncology Group phase III trial reported in the Journal of Clinical Oncology, Gamis et al found that the addition of gemtuzumab ozogamicin (Mylotarg), an immunoconjugate targeting CD33, resulted in significantly prolonged event-free survival but not overall survival when added...
Medicaid or No Insurance Associated With Worse Cancer-Specific Survival in Nonelderly Patients
In a study reported in the Journal of Clinical Oncology, Walker et al found that among nonelderly patients with the top 10 most lethal cancers, those with Medicaid or no insurance were more likely to present with advanced disease and less likely to receive cancer-directed surgery or radiation...
Large Differences in Survival According to Hospital Risk-Adjusted Margin Positivity Rate Status in Rectal Cancer Surgery
Risk-adjusted margin positivity rate has been suggested for use as a rectal cancer surgery quality metric. In an observational cohort study reported in the Journal of Clinical Oncology, Massarweh et al from The University of Texas MD Anderson Cancer Center identified risk-adjusted margin positivity ...
Statin Use After Colorectal Cancer Diagnosis Reduces Colorectal Cancer–Specific and All-Cause Mortality
In a UK population-based cohort study reported in the Journal of Clinical Oncology, Cardwell et al found that statin use after diagnosis of colorectal cancer was associated with a 29% reduction in colorectal cancer–specific mortality and a 25% reduction in all-cause mortality. Improvements...
Increases Seen in Use of Digital Mammography and Related Screening Costs in Medicare Population, but No Increase in Early Detection
In a study of use of breast cancer screening modalities in the Medicare population reported in the Journal of the National Cancer Institute, Killelea et al found significant increases in use of digital image acquisition and computer-aided detection and cost of screening, but no increase in rate of...
No Difference in Complication Rates or Hospital Stay With Robot-Assisted vs Open-Surgery Cystectomy in Bladder Cancer
In a trial reported in The New England Journal of Medicine, Bochner et al found no difference in complication rates or length of hospital stay with robot-assisted laparoscopic radical cystectomy vs open surgery in patients with bladder cancer. Blood loss was greater and procedure time shorter with...
Patient Navigation Significantly Improves Receipt of Antiestrogen Therapy but Not Radiation Therapy After Lumpectomy in Breast Cancer Patients
An analysis in the population of the National Patient Navigation Research Program reported by Ko et al in the Journal of Clinical Oncology indicates that patient navigation significantly improves the likelihood of receiving antiestrogen treatment among hormone receptor–positive breast cancer...
Taiwanese Study Shows Increased Risk of Head and Neck Cancer in Patients With Diabetes
In a Taiwanese retrospective cohort study reported in JAMA Otolaryngology–Head & Neck Surgery, Tseng et al found that diabetes was associated with increased risk of head and neck cancer, including increased risk of oral cavity, oropharyngeal, and nasopharyngeal cancers. Study Details...
High Prevalence of and Shorter Survival With MYD88 Mutation in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg-Type
The activating mutation MYD88 L265P has been reported in approximately two-thirds of cases of primary cutaneous diffuse large B-cell lymphoma, leg-type. In a French retrospective analysis reported in JAMA Dermatology, Pham-Ledard et al confirmed the high prevalence of the mutation and documented...
Higher Stromal Tumor-Infiltrating Lymphocyte Level Associated With Improved Outcome in Triple-Negative Breast Cancer
In an analysis of patients with operable triple-negative breast cancer in two Eastern Cooperative Oncology Group (ECOG) adjuvant trials, Adams and colleagues found that higher stromal compartment tumor-infiltrating lymphocyte levels were associated with significantly improved disease-free survival, ...
Tumor Downstaging After Neoadjuvant Chemotherapy Strongly Predicts Improved Outcome After Surgery in Esophageal and Esophagogastric Junction Cancer
In a European analysis reported in the Journal of Clinical Oncology, Davies et al found that pathologic tumor downstaging after neoadjuvant chemotherapy was the strongest independent predictor of overall survival in patients undergoing surgery for esophageal and esophagogastric junction...
PIK3CA Mutation Does Not Predict Outcome in Patients With Luminal Breast Cancer Receiving Endocrine Therapy
In a study reported in the Journal of Clinical Oncology, Sabine et al found that PIK3CA mutation was not an independent predictor of distant relapse-free survival among postmenopausal women with estrogen receptor–positive breast cancer receiving endocrine therapy in the TEAM (Exemestane...
HLA Matching Finds Suitable Donors for Majority of Hematopoietic Stem Cell Transplant Candidates
A study reported by Gragert et al in The New England Journal of Medicine indicates that most candidates for hematopoietic stem cell transplantation in the United States will have a suitable adult donor on the basis of HLA matching, although many will not have optimal donors. Few will have optimal...
Phase II Trial Shows Activity of Pemetrexed Plus Cisplatin in Treatment of Advanced, Persistent, or Recurrent Cervical Carcinoma
In a phase II Gynecologic Oncology Group (GOG) trial reported in the Journal of Clinical Oncology, Miller et al found that the combination of pemetrexed (Alimta) and cisplatin produced responses in the treatment of advanced, persistent, or recurrent cervical cancer. In the study, 54 patients from...
Musculoskeletal Pain May Be Sign of Potential Tyrosine Kinase Inhibitor Withdrawal Syndrome in CML
In a letter to the Journal of Clinical Oncology, Richter et al describe a potential tyrosine kinase inhibitor withdrawal syndrome characterized by musculoskeletal pain after stopping tyrosine kinase inhibitor treatment for chronic myeloid leukemia (CML). Onset After Tyrosine Kinase Inhibitor...
Minimal Residual Disease–Based Risk-Directed Therapy Is Effective in Children With BCR-ABL1–Like B-Cell ALL
BCR-ABL1–like acute lymphoblastic leukemia (ALL), a recently identified B-cell ALL subtype associated with poor outcome, has a gene-expression profile similar to BCR-ABL1–positive disease without the presence of the BCR-ABL1 fusion protein. In a retrospective analysis reported in the...
Anti–IL-6 Antibody Siltuximab Produces Durable Responses in Multicentric Castleman's Disease
Multicentric Castleman’s disease is characterized by overproduction of interleukin-6 (IL-6). In a trial reported in The Lancet Oncology, van Rhee et al found that the anti–IL-6 antibody siltuximab (Sylvant) produced a significantly better response rate vs placebo in patients with the...
African Americans More Likely Than Whites to Receive Analgesic With Toxic Metabolite for Cancer Pain
A study reported by Meghani et al in the Journal of Clinical Oncology showed that African American patients with cancer pain are more likely than white patients to receive morphine, with its known 3- and 6-glucuronide neurotoxic metabolites, despite their higher reported risk for chronic kidney...
Phase Ib Study Shows Activity of Ibrutinib Plus R-CHOP in First-Line Treatment of CD20-Positive B-Cell Non-Hodgkin Lymphoma
The oral Bruton's tyrosine kinase inhibitor ibrutinib (Imbruvica) has shown activity in relapsed and refractory B-cell malignancies. In a phase Ib trial reported in The Lancet Oncology, Younes et al identified no maximum tolerated dose of ibrutinib when combined with R-CHOP (rituximab [Rituxan],...
Promising Phase Ib Findings With Combined BRAF and MEK Inhibition With Vemurafenib and Cobimetinib in Advanced BRAF V600–Mutant Melanoma
In a phase Ib study reported in The Lancet Oncology, Ribas et al found that the combination of the BRAF inhibitor vemurafenib (Zelboraf) and the MEK inhibitor cobimetinib was safe and active in the treatment of advanced BRAF V600–mutant melanoma. Preclinical studies have shown that the...
Study Identifies Prevalence of Uterine Malignancy and Endometrial Hyperplasia at Time of Morcellation for Hysterectomy
There is considerable concern that uterine morcellation as part of minimally invasive hysterectomy may result in the spread of undetected malignancies. In a study reported in JAMA, Wright et al identified a prevalence of 27 cases of uterine cancer and 7 cases of other gynecologic malignancies per...
Phase II Trial Supports Use of First-Line Sunitinib vs Everolimus in Sequential Therapy in Metastatic Renal Cell Carcinoma
As reported by Motzer et al in the Journal of Clinical Oncology, the randomized phase II RECORD-3 trial showed that first-line use of everolimus did not achieve noninferiority in progression-free survival vs sunitinib (Sutent) in patients with metastatic renal cell carcinoma receiving sequential...
Adding Induction Chemotherapy to Chemoradiotherapy Does Not Improve Survival in Patients With N2 or N3 Locally Advanced Head and Neck Cancer
In a phase III trial reported in the Journal of Clinical Oncology, Cohen et al found that induction chemotherapy before chemoradiotherapy did not improve overall survival vs chemoradiotherapy alone in patients with N2 or N3 locally advanced squamous cell carcinoma of the head and neck. The study...
Dutch Phase II Study Supports Phase III Evaluation of Bevacizumab Plus Lomustine, but Not Bevacizumab Alone, in Recurrent Glioblastoma
Bevacizumab (Avastin) is frequently used in patients with recurrent glioblastoma, although it is unclear whether responses observed with such treatment result in improved overall survival. In the phase II Dutch BELOB study reported in The Lancet Oncology, Taal et al found that overall survival...
Higher Plasma Vitamin D Concentration Associated With Reduced Cancer-Specific and All-Cause Mortality After Diagnosis of Colorectal Cancer
In a Scottish study reported in Journal of Clinical Oncology, Zgaga et al found strong associations between plasma levels of 25-hydroxyvitamin D (25-OHD) after a diagnosis of colorectal cancer and colorectal cancer–specific and all-cause mortality. Significant interactions of vitamin D...
Combined BRAF V600E and TERT Promoter Mutations Identify Aggressive and Recurrent Papillary Thyroid Cancer
In a study reported in Journal of Clinical Oncology, Xing et al found that the combined presence of BRAF V600E and TERT C228T mutations was associated with increased risk of recurrence and poor disease-free survival in patients with papillary thyroid cancer. The retrospective study included 365...
Study Suggests That Primary Androgen-Deprivation Therapy Does Not Improve Long-Term Survival in Older Patients With Localized Prostate Cancer
Primary androgen-deprivation therapy has been widely used in localized prostate cancer, despite absence of definitive evidence of benefit in early-stage disease. In a large population-based cohort study reported in JAMA Internal Medicine, Lu-Yao et al found that primary androgen-deprivation therapy ...
Corticosteroids Improve Fatigue, Appetite Loss, and Patient Satisfaction but Not Pain in Opioid-Treated Advanced Cancer Patients, Small Study Shows
In a small Norwegian study reported in the Journal of Clinical Oncology, Paulsen et al found that methylprednisolone treatment improved fatigue, appetite loss, and patient satisfaction but not pain in patients with advanced cancer receiving opioid treatment for pain. Study Details In the study,...
